MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.

Price Chart

Executive Summary

Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million term loan and $30.0 million revolving credit facility, maturing June 2, 2032. Proceeds from the new term loan, combined with ~$98.5 million cash on hand, were used to repay $242.9 million in prior debt, reducing total debt by ~$92.9 million and extending the maturity from October 2027 to June 2032. The transaction materially reduces leverage, extends runway, and maintains liquidity, though a variable-rate interest structure introduces rate exposure.

Key Financial Metrics

Actionable Insight

Key Facts

• New $150.0M term loan facility and $30.0M revolver, both maturing June 2, 2032; new term loan reduces outstanding debt from ~$242.9M to $150.0M.
• Proceeds from the new term loan plus ~$98.5M cash on hand used to fully prepay and terminate the prior Credit Agreement (due October 2027).
• Interest rate: Term SOFR + 5.00% per annum; stepdown to 4.75% if first lien net leverage ratio ≤ 3.00x.
• Financial covenant (springing): if revolver usage ≥ 40% of commitments, max first lien net leverage ratio of 6.50x.
• No material revenue or earnings figures reported in the filing.
• Credit agreement is secured by substantially all assets of material domestic subsidiaries and guaranteed by Topco and its material domestic subsidiaries.

Financial Impact

Debt reduced from ~$242.9M to $150.0M; maturity extended by ~5 years; $30.0M revolver provides undrawn liquidity.

Risk Factors

• Variable-rate exposure on $150M term loan tied to Term SOFR; rising rates increase interest expense.
• Prior historical mis-scoring at impact=6 (T+20 -4.60%) suggests the market may not fully price this as a strong credit event; calibrate expectations.
• $98.5M cash depletion reduces balance sheet cash buffer.

Market Snapshot

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status